search
Back to results

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans (#6113)

Primary Purpose

Healthy, Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Metformin
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Healthy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects self-identify racial background, identify themselves, parents and four grandparents as African American
  • Subject status is healthy volunteer from t In the event that diabetes is indicated in a normal subject based on OGTT results, we will notify the patients' primary care physician. he SOPHIE cohort OR diagnosis of T2DM based on American Diabetes Association (ADA) criteria
  • Subjects over 18 years old and below 60 years
  • Subjects who are healthy on the basis of medical history, physical examinations and laboratory tests if healthy volunteer from SOPHIE
  • Subjects who agree with the written informed consent to participate in the study

Exclusion Criteria:

  • Unable to confirm African-American ethnicity
  • Under 18 years old
  • Pregnant or lactating women (female subjects will have a urine pregnancy test at the screening visit).
  • Prior history of any allergic reaction to metformin
  • Has a risk of congestive heart failure requiring pharmacologic treatment (medical history)
  • Has a prior history of renal* or hepatic dysfunction (renal and hepatic function will be evaluated based on screening blood tests conducted prior to study enrollment)
  • Risk of urinary or gastric retention or narrow-angle glaucoma (by medical history examination)
  • Impaired renal function (e.g as suggested by abnormal creatinine clearance, eGFR <60 or serum creatinine >1.4 mg/dl in females and >1.5 mg/dl in males) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction (heart attack), and septicemia, abnormal heart rhythms (tachyarrhythmias; heart beat > 100 beats per minute).
  • Impaired hepatic function (> 1.5 times the upper limit of normal)
  • Evidence of anemia (hemoglobin <10 g)
  • Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine.
  • They do not provide consent to participate in the study.

Sites / Locations

  • San Francisco General Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Metformin

Arm Description

Subjects will be given an oral dose of metformin once per day for two days.

Outcomes

Primary Outcome Measures

Renal Clearance of the Metformin
To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered pharmacokinetics of metformin.
Plasma glucose
To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered glucose lowering response to metformin.

Secondary Outcome Measures

Full Information

First Posted
August 1, 2012
Last Updated
October 21, 2014
Sponsor
University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT01681693
Brief Title
Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans
Acronym
#6113
Official Title
Effect of Genetic Variants in MATE1 and OCT3 Transporters on the Pharmacodynamics of Metformin in African Americans With Type II Diabetes Mellitus.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
July 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.
Detailed Description
To investigate the potential association of polymorphic genetic variants MATE1 and OCT3 with altered response to metformin, a genotype to phenotype strategy is employed. Specifically, the investigators will evaluate this hypothesis in African-Americans, a population which has a high incidence of type 2 diabetes and which has high variant allele frequencies (44.5% for MATE1-66T>C and 11.3% in OCT3-81G>delGA) relative to other ethic groups. To assess the effects of these variants on metformin response, the investigators will measure metformin renal clearance (pharmacokinetics of metformin), and plasma glucose and insulin levels (pharmacodynamic response) in healthy and diabetic patients who carry either the reference or variant alleles.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metformin
Arm Type
Experimental
Arm Description
Subjects will be given an oral dose of metformin once per day for two days.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
GLUCOPHAGE
Intervention Description
Subjects will be given an oral dose of metformin once per day for two days.
Primary Outcome Measure Information:
Title
Renal Clearance of the Metformin
Description
To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered pharmacokinetics of metformin.
Time Frame
24 hours post-dose
Title
Plasma glucose
Description
To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered glucose lowering response to metformin.
Time Frame
0, 15, 30, 45, 60, 90, 120, 180 minutes after glucose administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects self-identify racial background, identify themselves, parents and four grandparents as African American Subject status is healthy volunteer from t In the event that diabetes is indicated in a normal subject based on OGTT results, we will notify the patients' primary care physician. he SOPHIE cohort OR diagnosis of T2DM based on American Diabetes Association (ADA) criteria Subjects over 18 years old and below 60 years Subjects who are healthy on the basis of medical history, physical examinations and laboratory tests if healthy volunteer from SOPHIE Subjects who agree with the written informed consent to participate in the study Exclusion Criteria: Unable to confirm African-American ethnicity Under 18 years old Pregnant or lactating women (female subjects will have a urine pregnancy test at the screening visit). Prior history of any allergic reaction to metformin Has a risk of congestive heart failure requiring pharmacologic treatment (medical history) Has a prior history of renal* or hepatic dysfunction (renal and hepatic function will be evaluated based on screening blood tests conducted prior to study enrollment) Risk of urinary or gastric retention or narrow-angle glaucoma (by medical history examination) Impaired renal function (e.g as suggested by abnormal creatinine clearance, eGFR <60 or serum creatinine >1.4 mg/dl in females and >1.5 mg/dl in males) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction (heart attack), and septicemia, abnormal heart rhythms (tachyarrhythmias; heart beat > 100 beats per minute). Impaired hepatic function (> 1.5 times the upper limit of normal) Evidence of anemia (hemoglobin <10 g) Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine. They do not provide consent to participate in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathleen M Giacomini, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
San Francisco General Hospital
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

We'll reach out to this number within 24 hrs